Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen
Summary by The AI Journal
2 Articles
2 Articles
All
Left
Center
Right
Can Automation Increase Investment in Gene Therapies?
The potential of gene therapies will only be realized if the manufacturing challenges can be resolved, and that’s a tricky task. “Gene therapies can be transformative,” says Charles Gersbach, PhD, a biomedical engineer at Duke University. “They can treat diseases that are otherwise untreatable, but—like any new modality—the potential that gene therapy has is matched with its complexities, which leads to some challenges.” One of the key challenge…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium